Skip to main content
Clinical Trials/NCT02708446
NCT02708446
Unknown
Phase 4

A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP)

Gynuity Health Projects4 sites in 4 countries320 target enrollmentMay 2014

Overview

Phase
Phase 4
Intervention
Mifepristone
Conditions
Legally Induced Abortion Without Mention of Complication
Sponsor
Gynuity Health Projects
Enrollment
320
Locations
4
Primary Endpoint
Rate of successful abortion by 24 hours
Last Updated
9 years ago

Overview

Brief Summary

The primary goal of this study is to directly compare repeat doses of sublingual and buccal routes of 400 mcg misoprostol following mifepristone for second trimester abortion in order to determine if sublingual route confers an advantage with respect to efficacy and median time to complete abortion.

Detailed Description

Eligible women 13-21 weeks gestation who give informed consent will be randomized to receive buccal or sublingual misoprostol. Participants will take 200mg mifepristone and return to the hospital 24 hours later to begin induction with misoprostol. 400mcg misoprostol will be given every 3 hours until the expulsion of the fetus and placenta.

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
December 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Gynuity Health Projects
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Meet criteria to obtain abortion
  • Present with closed cervical os and no vaginal bleeding
  • Live fetus at time of presentation for service
  • Have no contraindications to study procedures, according to provider
  • Be able to consent to procedure, either by reading consent document or by having consent document read to her
  • Be willing to follow study procedures

Exclusion Criteria

  • Known previous transmural uterine incision
  • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  • Any contraindications to vaginal delivery
  • Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

Arms & Interventions

Sublingual misoprostol

200mg mifepristone + 400mcg sublingual misoprostol q3h

Intervention: Mifepristone

Sublingual misoprostol

200mg mifepristone + 400mcg sublingual misoprostol q3h

Intervention: Sublingual misoprostol

Buccal misoprostol

200mg mifepristone + 400mcg buccal misoprostol q3h

Intervention: Mifepristone

Buccal misoprostol

200mg mifepristone + 400mcg buccal misoprostol q3h

Intervention: Buccal misoprostol

Outcomes

Primary Outcomes

Rate of successful abortion by 24 hours

Time Frame: 24 hours following the start of misoprostol

Defined as complete evacuation of uterus at 24 hours following start of misoprostol, using study drugs without recourse to any additional intervention.

Rate of successful abortion by 48 hours

Time Frame: 48hours following the start of misoprostol

Defined as complete evacuation of uterus at 48 hours following start of misoprostol, using study drugs without recourse to any additional intervention.

Secondary Outcomes

  • Median time from first dose of misoprostol to complete expulsion of complete expulsion (provider diagnosis of complete expulsion of fetus and placenta).(48 hours)
  • Pain scale (1-7) as reported by women on questionnaire(from first drug dose to complete expulsion as documented on study forms, up to 72 hours)
  • Percentage of patients requiring provision of additional interventions.(from first drug dose to complete expulsion as documented on study forms, up to 72 hours)
  • Total number of doses of misoprostol.(from first drug dose to complete expulsion as documented on study forms, up to 72 hours)
  • Women's acceptability of the assigned method based on 5 point acceptability scale in questionnaire(from first drug dose to complete expulsion as documented on study forms, up to 72 hours)
  • Rates of heavy bleeding, uterine rupture, or infection requiring additional treatment(1 month)

Study Sites (4)

Loading locations...

Similar Trials